Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
J Crit Care ; 41: 124-129, 2017 10.
Article in English | MEDLINE | ID: mdl-28525777

ABSTRACT

PURPOSE: To measure the prevalence of elevated Endotoxin Activity (EA) in a large cohort of patients with Septic Shock (SS), and to assess its value as an early indicator of Gram-Negative (GN) infection, disease severity, and patient risk. MATERIALS AND METHODS: Adult patients were enrolled in this observational study if an EA determination was obtained within 24-h from SS onset. Demographic, clinical, and microbiological data were collected. In-hospital follow-up was also conducted. RESULTS: A high prevalence of endotoxemia was observed in the 107 subjects included, with 82% of patients showing either intermediate (≥0.4 units), or high (≥0.6) EA. Patients with positive cultures for GNs showed a higher mean EA (0.63±0.18 vs. 0.53±0.22; p<0.05). However, the test showed poor accuracy in the identification of GN bacteria as SS causative agents. Significantly higher lactate concentration (p=0.006), SOFA (p=0.04) and inotropic score (p=0.006) were observed in patients with endotoxemia. However, higher EA levels neither influenced mortality, nor length of stay. CONCLUSIONS: Early after SS onset, patients showed a high prevalence of endotoxemia, particularly those infected with GN bacteria. The EA assay might be a useful marker of disease severity. The complexity of such patients, however, limits EA accuracy in identifying GN sepsis and predicting outcome.


Subject(s)
Endotoxemia/epidemiology , Endotoxins/metabolism , Shock, Septic/metabolism , Adult , Aged , Bacteremia/complications , Biomarkers/metabolism , Cohort Studies , Endotoxemia/microbiology , Female , Gram-Negative Bacterial Infections/metabolism , Humans , Male , Middle Aged , Predictive Value of Tests , Prevalence , Prognosis , Severity of Illness Index , Shock, Septic/microbiology , Shock, Septic/mortality
2.
Autoimmun Rev ; 15(2): 146-54, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26527329

ABSTRACT

Autoantibodies to M-type phospholipase A2 receptor (PLA2R) are specific markers of idiopathic membranous nephropathy (IMN). They can differentiate IMN from other glomerular diseases and primary from secondary forms of MN. Preliminary data suggest that anti-PLA2R antibody titer correlates with disease activity but more solid evidence is needed. To evaluate the performance of anti-PLA2R antibody for monitoring nephropathy activity, 149 anti-PLA2R antibody measurements were performed during the follow-up of 42 biopsy proven IMN consecutive patients. Patients were enrolled either at time of diagnosis (33 cases, inception cohort) or after diagnosis (9 patients, non-inception cohort). Anti-PLA2R detection was performed using the highly sensitive transfected cell-based indirect immunofluorescence (IIFT). Over the follow-up there was a linear time-trend of decreasing proteinuria (P<0.001), increasing serum albumin (P<0.001) and decreasing PLA2R antibody levels (P=0.002). There was a statistically significant association between changes in PLA2R antibody levels and the clinical course of PLA2R-positive IMN. The positive PLA2R serum antibody status was linearly associated with increasing proteinuria and decreasing serum albumin over time, compared with negative antibody status. Moreover, the strong correlation between the clinical conditions and PLA2R antibody levels allowed the prediction of prevalence distribution of patients with active disease, partial and complete remission. Over the course of the follow-up, the probability of halving proteinuria increased 6.5 times after disappearance of PLA2R antibodies. Our data suggest that the serial evaluation of anti-PLA2R antibodies could help in optimal timing and duration of the immunosuppressive therapy, reducing over(under)-treatment and associated side-effects.


Subject(s)
Autoantibodies/blood , Glomerulonephritis, Membranous/diagnosis , Glomerulonephritis, Membranous/immunology , Receptors, Phospholipase A2/immunology , Autoantibodies/immunology , Biomarkers/blood , Biopsy , Humans
3.
Dig Liver Dis ; 47(10): 842-6, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26141927

ABSTRACT

BACKGROUND: Community acquired-Clostridium difficile infection (CDI) has increased also in children in the last years. AIMS: To determine the incidence of community-acquired CDI and to understand whether Clostridium difficile could be considered a symptom-triggering pathogen in infants. METHODS: A five-year retrospective analysis (January 2007-December 2011) of faecal specimens from 124 children hospitalized in the Niguarda Ca' Granda Hospital for prolonged or muco-haemorrhagic diarrhoea was carried out. Stool samples were evaluated for common infective causes of diarrhoea and for Clostridium difficile toxins. Patients with and without CDI were compared for clinical characteristics and known risk factors for infection. RESULTS: Twenty-two children with CDI were identified in 5 years. An increased incidence of community-acquired CDI was observed, ranging from 0.75 per 1000 hospitalizations in 2007 to 9.8 per 1000 hospitalizations in 2011. Antimicrobial treatment was successful in all 19 children in whom it was administered; 8/22 CDI-positive children were younger than 2 years. No statistically significant differences in clinical presentation were observed between patients with and without CDI, nor in patients with and without risk factors for CDI. CONCLUSIONS: Our study shows that Clostridium difficile infection is increasing and suggests a possible pathogenic role in the first 2 years of life.


Subject(s)
Anti-Infective Agents/therapeutic use , Clostridioides difficile , Clostridium Infections/epidemiology , Community-Acquired Infections/epidemiology , Diarrhea/epidemiology , Adolescent , Age Factors , Child , Child, Preschool , Clostridium Infections/drug therapy , Community-Acquired Infections/drug therapy , Diarrhea/microbiology , Female , Hospitalization , Humans , Incidence , Infant , Male , Retrospective Studies , Risk Factors
4.
J Travel Med ; 19(6): 387-90, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23379711

ABSTRACT

Rhinoscleroma is a chronic indolent granulomatous infection of the nose and the upper respiratory tract caused by Klebsiella rhinoscleromatis; this condition is endemic to many regions of the world including North Africa. We present a case of rhinoscleroma in a 51-year-old Egyptian immigrant with 1-month history of epistaxis. We would postulate that with increased travel from areas where rhinoscleroma is endemic to other non-endemic areas, diagnosis of this condition will become more common.


Subject(s)
Anti-Bacterial Agents , Ethmoid Sinus/pathology , Klebsiella pneumoniae , Rhinoscleroma , Staphylococcus aureus , Turbinates/pathology , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/classification , Biopsy , Epistaxis/etiology , Ethmoid Sinus/microbiology , Humans , Klebsiella pneumoniae/drug effects , Klebsiella pneumoniae/isolation & purification , Magnetic Resonance Imaging/methods , Male , Microbial Sensitivity Tests/methods , Middle Aged , Rhinoscleroma/complications , Rhinoscleroma/diagnosis , Rhinoscleroma/drug therapy , Rhinoscleroma/etiology , Rhinoscleroma/physiopathology , Staphylococcus aureus/drug effects , Staphylococcus aureus/isolation & purification , Tomography, X-Ray Computed/methods , Treatment Outcome , Turbinates/microbiology
5.
Diagn Microbiol Infect Dis ; 69(4): 363-9, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21396530

ABSTRACT

Beginning on April 2007, a prospective multicenter study was performed to investigate prevalence and epidemiology of microbial pathogens causing bloodstream infections (BSIs). Twenty microbiology laboratories participated to the survey over a 1-year period. A total of 11,638 episodes of BSI occurred in 11 202 patients, with 8.5% (n=985) of episodes being polymicrobial. Of 12 781 causative organisms, aerobic Gram-negative bacteria were 47.4% (n=6058), whereas Gram-positives accounted for 43.9% (n=5608). The remaining organisms included fungal species (n=924, 7.2%) and anaerobes (n=191, 1.5%). The most prevalent agents were Escherichia coli (21.7%), Staphylococcus aureus (14.9%), Staphylococcus epidermidis (8.2%), Pseudomonas aeruginosa (7.0%), and Enterococcus faecalis (6.3%). Isolates recovered from patients admitted to medical, surgical, and intensive care units accounted for 62.9%, 17.7%, and 19.4% of cases, respectively. BSIs were classified as hospital-acquired in 67.2% of cases. Compared with previous studies, our data show an increasing role of Gram-negative bacteria among both hospital- and community-acquired blood isolates.


Subject(s)
Bacteremia/microbiology , Gram-Negative Bacteria/isolation & purification , Gram-Positive Bacteria/isolation & purification , Adolescent , Adult , Aged , Bacteremia/epidemiology , Community-Acquired Infections/epidemiology , Community-Acquired Infections/microbiology , Cross Infection/epidemiology , Cross Infection/microbiology , Female , Gram-Negative Bacteria/classification , Gram-Positive Bacteria/classification , Humans , Italy/epidemiology , Male , Middle Aged , Prevalence , Prospective Studies
6.
Leuk Lymphoma ; 49(11): 2148-55, 2008 Nov.
Article in English | MEDLINE | ID: mdl-19021058

ABSTRACT

Indwelling central venous catheters (CVCs) are used in the management of hematologic patients. However, insertion and maintenance of CVCs are susceptible to complications. Study design and methods data concerning 388 consecutive catheterisations, performed in oncohematologic patients between April 2003 and December 2004, were prospectively collected. At insertion thrombocytopenia was present in 109 cases (28.1%) and neutropenia in 67 (17.3%). Hemorrhage after CVC insertion occurred in five thrombocytopenic patients (1.3%). The median duration of catheterisation was 18.8 days (range 1-89), longer in the 7-French CVCs utilised in leukemic patients (24.3 days) and shorter in 12-French CVCs (11 days), used for PBSC harvesting. Deep venous thrombosis was diagnosed in 13 cases (3.3%). Ninety-two catheterisations (12.6/1000 days-catheter) were complicated by infections: 19 local infections (4.8%) and 73 (18.8%) bacteraemias of which 45 (11.6%) were catheter-related, mainly due to Gram positive germs (32/45, 71.1%). The frequency of catheter-related bacteraemia was 7.2 events/1000 days-catheter. Thirteen CVCs were removed due to thrombosis, 15 due to infections, 20 due to malfunction, the remaining 333 at patients discharge. At univariate analysis high-dose chemotherapy (p = 0.013), 7-Fr lumen (p = 0.023), acute myeloid leukemia (AML) (p = 0.001), duration of neutropenia >10 days and length of catheterisation were significantly correlated to infection. Multivariate analysis confirmed the duration of catheterisation, AML and high-dose chemotherapy as risk factors. Even though hematological in-patients are at increased risk for bleeding and infections, non-tunnelled CVCs offer a safe venous access also in patients affected by severe thrombocytopenia and prolonged neutropenia.


Subject(s)
Catheterization, Central Venous/adverse effects , Hematologic Diseases/complications , Aged , Aged, 80 and over , Analysis of Variance , Bacteremia/etiology , Catheterization, Central Venous/statistics & numerical data , Child, Preschool , Female , Hematologic Diseases/therapy , Hemorrhage/etiology , Humans , Infections/etiology , Male , Middle Aged , Neutropenia/etiology , Prospective Studies , Risk Factors , Thrombocytopenia/etiology , Time Factors , Venous Thrombosis/etiology
7.
Diagn Microbiol Infect Dis ; 55(4): 311-8, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16678993

ABSTRACT

We evaluated the ability of 60 Italian clinical microbiology laboratories in detecting and reporting beta-lactam resistance phenotypes in Enterobacteriaceae. Laboratories received 5 well-characterized isolates producing extended-spectrum beta-lactamases (ESBLs), 2 hyperproducers of chromosomal enzymes, and 3 quality control strains. The performances in antimicrobial susceptibility testing (AST) were different depending on the species and type of ESBL produced. High rates of very major errors (up to 56%) were observed for ESBL producers when testing cephalosporins and aztreonam, especially in the case of CTX-M-1-producing Escherichia coli and TEM-52-producing Proteus mirabilis. Isolates hyperproducing chromosomal enzymes were erroneously reported as ESBL producers in approximately 20% of cases. Detection of ESBLs is still a problem for clinical microbiology laboratories. Overall, performances in AST appear to be better with Klebsiella spp. producing well-known enzymes (e.g., SHV type) than with strains producing emerging enzymes (e.g., CTX-M type) or organisms not well recognized as ESBL producers (e.g., P. mirabilis).


Subject(s)
Enterobacteriaceae/drug effects , Laboratories, Hospital/standards , beta-Lactam Resistance , Enterobacteriaceae/classification , Humans , Italy , Microbial Sensitivity Tests/standards , Phenotype , Quality Control
SELECTION OF CITATIONS
SEARCH DETAIL
...